Celltrion Pharm, Inc.
Quick facts
Marketed products
- Pioglitazone + Alogliptin · Diabetes
Pioglitazone improves insulin sensitivity by activating PPAR-γ, while alogliptin inhibits DPP-4 to increase incretin levels, together reducing blood glucose in type 2 diabetes.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: